Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study.
DAA
HCV
HIV
co-infection
contraindications
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
received:
07
04
2022
accepted:
22
06
2022
pubmed:
9
8
2022
medline:
16
2
2023
entrez:
8
8
2022
Statut:
ppublish
Résumé
Our objective was to determine whether antiretroviral drugs (ARVs) were used according to the European AIDS Clinical Society (EACS) guidelines for people with HIV/hepatitis C virus (HCV) coinfection treated with direct-acting antivirals (DAAs) between 30 November 2014 and 31 December 2019 in the pan-European EuroSIDA study. At each publication date of the EACS guidelines, plus 3 and 6 months, we calculated the number of people receiving DAAs with potential and actual ARV contraindications ('red shading' in the EACS guidelines). We used logistic regression to investigate factors associated with using contraindicated ARVs. Among 1406 people starting DAAs, the median age was 51 years, 75% were male, 57% reported injected drug use as an HIV risk, and 76% were from western Europe. Of 1624 treatment episodes, 609 (37.5%) occurred while the patient was receiving ARVs with potential contraindications; among them, 38 (6.2%; 95% confidence interval [CI] 4.3-8.2) involved a contraindicated ARV (18 non-nucleoside reverse transcriptase inhibitors), 16 involved protease inhibitors, and four involved integrase strand transfer inhibitors. The adjusted odds of receiving a contraindicated ARV were higher (3.25; 95% CI 1.40-7.57) among participants from east/central east Europe (vs. south) and lower (0.22; 95% CI 0.08-0.65) for 2015-2018 guidelines (vs. 2014). In total, 29 of the 32 (90.6%) patients receiving a contraindicated ARV and 441 of the 461 (95.7%) with potential ARV contraindications experienced a sustained virological response ≥12 weeks after stopping treatment (SVR12; p = 0.55). In this large heterogenous European cohort, more than one-third of people with HIV/HCV coinfection received DAAs with potential ARV contraindications, but few received a contraindicated ARV. Use of contraindicated ARVs declined over time, corresponding to the increased availability of ARV therapy regimens without interactions with DAA across Europe. Participants who received a contraindicated DAA and ARV combination still had a high rate of SVR12.
Substances chimiques
Antiviral Agents
0
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
224-230Informations de copyright
© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C. J Hepatol. 2018;69(2):461-511.
European AIDS Clinical Society. EACS Guidelines. Version 11.0. October 2021. Accessed October 13, 2021. https://www.eacsociety.org/media/final2021eacsguidelinesv11.0_oct2021.pdf.
Neant N, Solas C. Drug-drug interactions potential of direct-acting antivirals for the treatment of chronic hepatitis C virus infection. Int J Antimicrob Agents. 2020;56(1):105571.
Smolders EJ, Smit C, de Kanter TMM, et al. Brief report: high need to switch cART or comedication with the initiation of DAAs in elderly HIV/HCV-coinfected patients. J Acquir Immune Defic Syndr. 2017;76(2):193-199.
Maistat L, Kravchenko N, Reddy A. Hepatitis C in Eastern Europe and Central Asia: a survey of epidemiology, treatment access and civil society activity in eleven countries. Hepatol Med Policy. 2017;2:9.
Colombo MG, Musabaev EI, Ismailov UY, et al. Consensus on management of hepatitis C virus infection in resource-limited Ukraine and commonwealth of independent states regions. World J Gastroenterol. 2019;25(29):3897-3919.
Laut K, Kirk O, Rockstroh J, et al. The EuroSIDA study: 25 years of scientific achievements. HIV Med. 2020;21(2):71-83.
Peters L, Laut K, Resnati C, et al. Uptake of hepatitis C virus treatment in HIV/hepatitis C virus-coinfected patients across Europe in the era of direct-acting antivirals. AIDS. 2018;32(14):1995-2004.
European AIDS Clinical Society. EACS Guidelines. Version 7.1. November 2014. Accessed October 13, 2021. https://www.eacsociety.org/media/guidelines-7.1-english.pdf.
European AIDS Clinical Society. EACS Guidelines. Version 8.0. October 2015. Accessed October 13, 2021. https://www.eacsociety.org/media/guidelines_8.0-english-revised_20160610.pdf.
European AIDS Clinical Society. EACS Guidelines. Version 8.1. October 2016. Accessed October 13, 2021. https://www.eacsociety.org/media/guidelines_8.1-english.pdf.
European AIDS Clinical Society. EACS Guidelines. Version 8.2. January 2017. Accessed October 13, 2021. https://www.eacsociety.org/media/guidelines_8.2-english.pdf.
European AIDS Clinical Society. EACS Guidelines. Version 9.1. October 2018. Accessed October 13, 2021. https://www.eacsociety.org/media/2018_guidelines-9.1-english.pdf.
Gokengin D, Oprea C, Begovac J, et al. HIV care in central and Eastern Europe: how close are we to the target? Int J Infect Dis. 2018;70:121-130.
Furihata T, Matsumoto S, Fu Z, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014;58(8):4555-4564.
Ouwerkerk-Mahadevan S, Snoeys J, Peeters M, Beumont-Mauviel M, Simion A. Drug-drug interactions with the NS3/4A protease inhibitor simeprevir. Clin Pharmacokinet. 2016;55(2):197-208.
Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral hepatitis C therapy: pharmacokinetic and Pharmacodynamic considerations: a 2019 update. Clin Pharmacokinet. 2019;58(10):1237-1263.